Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC

SummaryNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/18/2013 | 08:46am EDT
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
09/19PFIZER : Description Statement of Changes in Beneficial Ownership
PU
09/19PFIZER : Presents Scientific Advancements in Cancer Care at the ESMO Congress 20..
BU
09/17PFIZER : Invites Public to View and Listen to Webcast of October 29 Conference C..
BU
09/17PFIZER : Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococc..
PU
09/16PFIZER : Description Statement of Changes in Beneficial Ownership
PU
09/13Biopharmaceutical Company Imara Inc. Files Confidentially for IPO
DJ
09/12PFIZER : Description Initial Statement of Beneficial Ownership
PU
09/12PFIZER : SpringWorks Therapeutics IPO Prices at High End of Range
DJ
09/12PFIZER : Catalia Health and Pfizer collaborate to better understand patient jour..
PU
09/12GLAXOSMITHKLINE : ViiV Healthcare - Stigma and mental health challenges remain b..
AQ
More news
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC201 939
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.14.65%243 639
MERCK AND COMPANY9.89%214 995
PFIZER-16.36%201 939
NOVARTIS15.63%198 194